8-K: Glaukos Reports Record Third Quarter Sales, Raises Full-Year Guidance

Glaukos Corporation announced record net sales for the third quarter of 2024, driven by strong growth in glaucoma and corneal health, and raised its full-year revenue guidance.

Summary

• Glaukos Corporation reported record net sales of $96.7 million for the third quarter of 2024, a 24% increase compared to the same period in 2023.
• Glaucoma net sales reached a record $76.0 million, a 30% year-over-year increase, while Corneal Health net sales were $20.6 million, a 5% increase.
• The company's gross margin was approximately 77%, with a non-GAAP gross margin of approximately 82%.
• Glaukos has raised its 2024 net sales guidance to a range of $377 million to $379 million, up from the previous range of $370 million to $376 million.
• The company ended the third quarter with approximately $267.2 million in cash and cash equivalents, short-term investments, and restricted cash.
• The company's GAAP net loss for the quarter was $21.4 million, or ($0.39) per diluted share, compared to a net loss of $30.4 million, or ($0.63) per diluted share, in the third quarter of 2023.
• Non-GAAP net loss for the quarter was $15.2 million, or ($0.28) per diluted share, compared to a non-GAAP net loss of $24.2 million, or ($0.50) per diluted share, in the third quarter of 2023.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to record sales, increased guidance, and progress in key product launches. While there are some challenges and risks, the overall tone is optimistic and forward-looking.

Positives

• Record net sales were achieved in the third quarter of 2024, demonstrating strong business momentum.
• Glaucoma sales showed significant growth, indicating strong market adoption of their products.
• The company's gross margin remains healthy, reflecting efficient operations.
• The increase in full-year revenue guidance suggests confidence in future performance.
• The company has a strong cash position, providing financial flexibility.
• The company has made progress in securing reimbursement for iDose TR and iStent infinite.
• The company has secured several international regulatory approvals, expanding its global reach.
• The company has a robust pipeline of novel, dropless platform technologies.

Negatives

• The company reported a GAAP net loss of $21.4 million for the quarter.
• Non-GAAP gross margin decreased slightly from 83% to 82% year-over-year.
• Selling, general and administrative expenses increased by 18% year-over-year.
• Research and development expenses increased by 4% year-over-year.
• The company is experiencing headwinds in the U.S. Corneal Health franchise due to entry into the MDRP.
• The company expects trialing of new competitive products in major international markets may become an increasing headwind in 2025.

Risks

• The company's ability to successfully commercialize iDose TR is subject to risks and uncertainties.
• Macroeconomic conditions, including foreign currency fluctuations, could impact the business.
• The company depends on a limited number of third-party suppliers.
• Disruptions at the company's primary facility could affect manufacturing capacity.
• Securing and maintaining adequate reimbursement for procedures is critical.
• The company faces risks related to compliance with laws and regulations.
• Clinical trials are lengthy and expensive, with uncertain outcomes.
• The company faces risks related to product recalls and safety issues.
• The company faces risks related to cyber threats and data privacy.
• The company faces risks related to protecting its intellectual property.
• The company faces risks related to servicing its indebtedness.

Future Outlook

Glaukos expects full-year 2024 global consolidated net sales of $377 $379 million, reflecting potential contributions from iDose TR and iStent infinite, as well as the impact of finalized MIGS LCDs and other factors.

Management Comments

• Our record third quarter results reflect successful global execution of our key strategic plans and continued strong momentum in our business, said Thomas Burns, Glaukos chairman and chief executive officer.
• We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.

Industry Context

Glaukos's results reflect a growing trend in the ophthalmic industry towards minimally invasive surgical options and sustained-release drug delivery systems for glaucoma and other eye diseases. The company's focus on innovative technologies like iDose TR and iStent aligns with the industry's push for more effective and patient-friendly treatments.

Comparison to Industry Standards

• Glaukos's 24% year-over-year revenue growth in Q3 2024 is strong compared to the broader medical device industry, which typically sees single-digit growth.
• Competitors in the MIGS space include companies like Ivantis and Alcon, but Glaukos is a leader in the space with a broad portfolio of products.
• The 82% non-GAAP gross margin is high for the medical device industry, indicating strong pricing power and efficient operations.
• The company's investment in R&D, with over $600 million since 2018, is significant and positions them well for future growth.
• The launch of iDose TR is a significant development, as it is a first-of-its-kind, long-duration, intracameral procedural pharmaceutical, setting it apart from competitors.

Stakeholder Impact

• Shareholders will benefit from the increased revenue and improved financial performance.
• Employees will benefit from the company's growth and success.
• Customers (ophthalmic surgeons and patients) will benefit from the company's innovative products and therapies.
• Suppliers will benefit from the company's increased demand for its products.
• Creditors will benefit from the company's strong financial position and reduced debt.

Next Steps

• The company will continue to advance commercial launch activities for iDose TR and iStent infinite.
• The company will continue to pursue market access initiatives to support consistent and dependable professional fee payment.
• The company will continue to advance its pipeline of novel, dropless platform technologies.
• The company is preparing to commence a Phase 3 clinical trial for iDose TREX by the end of 2024.
• The company is targeting clinical study commencement for PRESERFLO MicroShunt in 1H 2025.

Key Dates

Keywords

Glaukos, glaucoma, corneal health, iDose TR, iStent, MIGS, ophthalmic, medical technology, revenue, financial results, reimbursement, clinical trials